共 15 条
- [1] Wu Z(2021)Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Lancet Infect Dis 21 803-812
- [2] Hu Y(2021)Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Lancet Infect Dis 21 181-192
- [3] Xu M(2020)Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial Lancet 396 1979-1993
- [4] Zhang Y(2020)Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine N Engl J Med 383 2603-2615
- [5] Zeng G(2002)The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI) Vaccine 21 298-302
- [6] Pan H(undefined)undefined undefined undefined undefined-undefined
- [7] Ramasamy MN(undefined)undefined undefined undefined undefined-undefined
- [8] Minassian AM(undefined)undefined undefined undefined undefined-undefined
- [9] Ewer KJ(undefined)undefined undefined undefined undefined-undefined
- [10] Polack FP(undefined)undefined undefined undefined undefined-undefined